CD133 negative cancer stem cells in glioblastoma

Front Biosci (Elite Ed). 2011 Jan 1;3:701-10. doi: 10.2741/e280.

Abstract

Glioblastomas (GBM) are paradigmatic for the investigation of cancer stem cells (CSC) in solid tumors. Recently, the discovery of CD133- CSC in addition to CD133+ CSC has substantially added to our understanding of the complexity of GBM CSC. This review gives an overview on our current knowledge on CD133- cells in GBM and describes five different hypothesizes on the nature of CD133- cells in GBM. In addition, we summarize the current knowledge on tumorigenic CD133- CSC, list available markers, describe the current controversies on the origin of CD133- CSC, and discuss how the heterogeneity of CSC may correspond to the molecular heterogeneity of GBM.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers, Tumor / metabolism*
  • Cell Differentiation / physiology*
  • Glioblastoma / metabolism*
  • Humans
  • Interleukin Receptor Common gamma Subunit / metabolism*
  • Neoplastic Stem Cells / metabolism*

Substances

  • Biomarkers, Tumor
  • IL2RG protein, human
  • Interleukin Receptor Common gamma Subunit